Evidence map›Paper›PMID 36643307›Full record

ArticleHeliyon2022

N-alkylimidazole derivatives as potential inhibitors of quorum sensing in

Caleb Nketia Mensah, Gilbert Boadu Ampomah, Jehoshaphat Oppong Mensah, Edward Ntim Gasu, Caleb Impraim Aboagye, Edmund Ekuadzi, Nathaniel Owusu Boadi, Lawrence Sheringham Borquaye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Anti-QS Strategies AgainstMicroorganisms · 2025
    Review
  4. Heliyon · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Caleb Nketia MensahDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Gilbert Boadu AmpomahDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Jehoshaphat Oppong MensahDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Edward Ntim GasuDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Caleb Impraim AboagyeDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Edmund EkuadziCentral Laboratory, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Nathaniel Owusu BoadiDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Lawrence Sheringham BorquayeDepartment of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Kwame Nkrumah University of Science and Technology · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance is a threat to global public health. Microbial resistance is mediated by biofilm formation and virulence behavior during infection. Quorum sensing (QS), a cell-to-cell communication is frequently used by microbes to evade host immune systems. Inhibiting QS channels is a potential route to halt microbial activities and eliminate them. Imidazole has been shown to be a potent warhead in various antimicrobial agents. This study aims to evaluate alkyl-imidazole derivatives as potential inhibitors of QS and to explore the interactions of the compounds with LasR, a key protein in the QS machinery of

Indexed as

Biofilm inhibitionImidazole derivativesLasRPyocyaninVirulence factor

Identifiers

PMID36643307
PMCPMC9834748
OpenAlexW4312132120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.